CytoComm™ for Oncology
CytoComm™ is being designed to allow wireless monitoring of targeted cellular responses in chemotherapy patients. CytoComm™ intends to provide more data and higher quality data to the physician during the treatment of patients.
Current drug dosing calculations are based on a patient’s height and weight, rather than actual, real-time physiological conditions. By sensing levels of medication and other markers within the patient, CytoComm™ is being built to provide real-time information from the patient’s own body. CytoComm™, as a result, should drive drug dosing for relatively constant levels of chemotherapy medication to be dispensed to the patient.
As shown above, Efferent Labs’ technology is designed to allow doctors to tailor a course of chemotherapy to the patient that should eliminate the dramatic swings in the administration of medication, and enable as never before, a scenario where a more consistent “just right” level of chemotherapy is possible.